Since aberrant Shh signaling occurs in pancreatic tumorigenesis, therapeutics that target Shh pathway may improve the outcomes of patients with pancreatic cancer by targeting CSCs and also facilitate development of mechanism-driven protocols for optimal clinical effects. Here, SHH is linked to familial pancreatic carcinoma.